Physician profile
Atulkumar D Patel
NPI 1033292685
$672.10
in general payments reported to CMS, 2019-2025
17 companies · $50.82 in 2025
The $50.82 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $385 · 2023: $125 · 2025: $50.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $118.80 | 2022 | |
| Beigene USA, INC. | $81.51 | 2021-2023 | Brukinsa |
| Janssen Biotech, INC. | $79.99 | 2022 | |
| Merck Sharp & Dohme LLC | $69.02 | 2021-2023 | Keytruda, Lynparza |
| Incyte Corporation | $67.44 | 2021-2023 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $34.74 | 2022 | |
| Abbvie INC. | $28.19 | 2025 | |
| Jazz Pharmaceuticals INC. | $23.46 | 2021 | |
| Geron Corporation | $22.63 | 2025 | Rytelo |
| Sandoz INC. | $21.66 | 2023 | Hyrimoz |
| Daiichi Sankyo INC. | $20.88 | 2022 | |
| Amgen INC. | $20.84 | 2022 | |
| Blueprint Medicines Corporation | $18.77 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.23 | 2023 | Lynparza |
| Glaxosmithkline, LLC. | $18.11 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $14.93 | 2022 | |
| Genentech USA, INC. | $12.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atulkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.